Dual Interleukin-4/Interleukin-13 Blocker-induced Arthralgia Treated Successfully with Upadacitinib in a Patient with Atopic Dermatitis

Takayuki Tanji; Daisuke Watabe; Nobuyuki Arakawa; Hirofumi Kamada; Hiroo Amano

doi:10.2340/actadv.v103.5326

Authors

Takayuki Tanji Department of Dermatology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695, Japan
Daisuke Watabe Department of Dermatology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695, Japan
Nobuyuki Arakawa Department of Dermatology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695, Japan
Hirofumi Kamada Department of Dermatology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695, Japan
Hiroo Amano Department of Dermatology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695, Japan

DOI:

https://doi.org/10.2340/actadv.v103.5326

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol 2018; 78: 53-62.

https://doi.org/10.1016/j.jaad.2017.12.019 DOI: https://doi.org/10.1016/j.jaad.2017.12.019

Thaçi D, Simpson EL, Deleuran M, Kataoka Y, Chen Z, Gadkari A, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci 2019; 94: 266-275.

https://doi.org/10.1016/j.jdermsci.2019.02.002 DOI: https://doi.org/10.1016/j.jdermsci.2019.02.002

Iwaszko M, Bialy S, Bogunia-Kubik K. Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis. Cells 2021; 10: 3000.

https://doi.org/10.3390/cells10113000 DOI: https://doi.org/10.3390/cells10113000

Lazarski CA, Ford J, Katzman SD, Rosenberg AF, Fowell DJ. IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance. PLoS One 2013; 8: e71949.

https://doi.org/10.1371/journal.pone.0071949 DOI: https://doi.org/10.1371/journal.pone.0071949

de Wijs LEM, van der Waa JD, de Jong PHP, Hijnen DJ. Acute arthritis and arthralgia as an adverse drug reaction to dupilumab. Clin Exp Dermatol 2020; 45: 262-263.

https://doi.org/10.1111/ced.14050 DOI: https://doi.org/10.1111/ced.14050

Willsmore ZN, Woolf RT, Hughes C, Menon B, Kirkham B, Smith CH, Pink AE. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol 2019; 181: 1068-1070.

https://doi.org/10.1111/bjd.18031 DOI: https://doi.org/10.1111/bjd.18031

Ishibashi M, Honda T, Tabuchi Y, Kabashima K. Polyenthesitis during treatment with dupilumab for atopic dermatitis. J Eur Acad Dermatol Venereol 2020; 34: e319-e321.

https://doi.org/10.1111/jdv.16239 DOI: https://doi.org/10.1111/jdv.16239

Arakawa N, Inoue T, Tanji T, Amano H. Development of arthralgia during treatment with dupilumab in a patient with atopic dermatitis. J Dermatol 2021; 48: e397-e398.

https://doi.org/10.1111/1346-8138.15965 DOI: https://doi.org/10.1111/1346-8138.15965

Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 2014; 134: 769-779.

https://doi.org/10.1016/j.jaci.2014.08.008 DOI: https://doi.org/10.1016/j.jaci.2014.08.008

Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 2017; 76: 736-744.

https://doi.org/10.1016/j.jaad.2016.12.005 DOI: https://doi.org/10.1016/j.jaad.2016.12.005